Your browser doesn't support javascript.
loading
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
Cortes, Jorge E; Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C; Crescenzo, Rocco J; Su, Yun; Gambacorti-Passerini, Carlo; Heeg, Bart; Douglas Smith, B.
Afiliação
  • Cortes JE; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
  • Muresan B; Ingress-Health, Rotterdam, The Netherlands.
  • Mamolo C; Patient & Health Impact, Pfizer Inc., Groton, CT, USA.
  • Cappelleri JC; Global Biometrics & Data Management, Pfizer Inc., Groton, CT, USA.
  • Crescenzo RJ; Worldwide Research & Development, Pfizer Inc., Walton Oaks, UK (at the time of this research).
  • Su Y; Patient & Health Impact, Pfizer Inc, New York, NY, USA (at the time of this research).
  • Gambacorti-Passerini C; Department of Hematology, University of Milano Bicocca, Monza, Italy.
  • Heeg B; Ingress-Health, Rotterdam, The Netherlands.
  • Douglas Smith B; Department of Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA.
Curr Med Res Opin ; 35(9): 1615-1622, 2019 09.
Article em En | MEDLINE | ID: mdl-30964361

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Quinolinas / Leucemia Mieloide de Fase Crônica / Dasatinibe / Compostos de Anilina / Nitrilas Tipo de estudo: Systematic_reviews Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Quinolinas / Leucemia Mieloide de Fase Crônica / Dasatinibe / Compostos de Anilina / Nitrilas Tipo de estudo: Systematic_reviews Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article